ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Background: Atopic dermatitis (AD) may be exacerbated by occlusion from items such as occlusive gloves or textiles, especially if the occlusion is removed suddenly, creating a steep humidity gradient.

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...

Introduction There are numerous new systemic treatments for atopic dermatitis in various stages of development and most are being compared with placebo rather than active comparators. In order to ...

In China, the number of patients with atopic dermatitis continues to ... and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Canada Inc. said it is disappointed and strongly disagrees with Canada’s Drug Agency’s Final Recommendation for Ebglyss, ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

If the patient has reported a history of steroid use, the first treatment step should be to discontinue the medication's use immediately. However, the patient should be aware that this may result ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...